Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA

Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA

Aim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). Patients & methods: Retrospective, observational study of IBM R MarketScan R...

Full description

Bibliographic Details
Main Authors:	Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi, Nupur Greene
Format:	Article
Language:	English
Published:	Becaris Publishing Limited 2022-11-01
Series:	Journal of Comparative Effectiveness Research
Subjects:	alemtuzumab disease-modifying therapies (dmts) healthcare costs healthcare resource utilization (hcru) inpatient outpatient people with multiple sclerosis (pwms) relapsing-remitting multiple sclerosis (rrms) usa

Similar Items

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States
by: Araujo L, et al.
Published: (2023-05-01)

Identification of Key Ferroptosis-Related Genes in the Peripheral Blood of Patients with Relapsing-Remitting Multiple Sclerosis and Its Diagnostic Value
by: Xi Song, et al.
Published: (2023-03-01)

Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis
by: Yeseul Kim, et al.
Published: (2018-10-01)

Headache first manifestation of Multiple Sclerosis (PP-19)
by: Fatemeh Abrishamchi
Published: (2023-01-01)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
by: Sofia Sandgren, et al.
Published: (2023-09-01)

Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis
by: Nupur Greene, et al.
Published: (2023-07-01)

Meccanismo d’azione dei farmaci più recenti, Teriflunomide e Alemtuzumab e implicazioni terapeutiche
by: Francesco Patti
Published: (2015-11-01)

A case of alemtuzumab-induced thyroid disease with a fluctuating course
by: Sarah Ali Alghamdi, et al.
Published: (2023-01-01)

Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up
by: Furkan Saridas, et al.
Published: (2024-03-01)

Listeria Meningitis with Aspergillosis After Alemtuzumab Treatment
by: Ahmet Kasım Kılıç, et al.
Published: (2022-03-01)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
by: Martin Vališ, et al.
Published: (2020-05-01)

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
by: Krista Barclay, et al.
Published: (2019-03-01)

Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis
by: Jonathan A. Gernert, et al.
Published: (2023-08-01)

Linear Modeling of Multiple Sclerosis and Its Subgroubs
by: Yeliz Karaca, et al.
Published: (2015-03-01)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
by: Trygve Holmøy, et al.
Published: (2019-08-01)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
by: Martha Rocio Hernández-Preciado, et al.
Published: (2022-06-01)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
by: Simona Rolla, et al.
Published: (2020-06-01)

Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany
by: Watson C, et al.
Published: (2017-02-01)

Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data
by: Jacqueline A. Nicholas, et al.
Published: (2019-10-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2024-02-01)

Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
by: Ratthaporn Boonsuth, et al.
Published: (2021-11-01)

Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses
by: Clara Hilger, et al.
Published: (2020-10-01)

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
by: A. G. Vakrakou, et al.
Published: (2018-10-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Clinical markers for unfavorable course of multiple sclerosis
by: Mariya S. Matrosova, et al.
Published: (2023-09-01)

Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
by: Aurora Zanghì, et al.
Published: (2020-02-01)

Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
by: Elisabetta Signoriello, et al.
Published: (2023-02-01)

Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis
by: Maria Pia Sormani, et al.
Published: (2020-09-01)

Clinical case of COVID-19 in a patient treated with alemtuzumab
by: E. V. Popova
Published: (2021-12-01)

Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
by: Fabian Maass, et al.
Published: (2021-02-01)

Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary‐progressive and relapsing‐remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases
by: Priyadarshi Prajjwal, et al.
Published: (2023-07-01)

Clinical efficacy and safety of alemtuzumab in postmarketing practice
by: N. V. Khachanova
Published: (2019-06-01)

Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies
by: Trygve Holmøy, et al.
Published: (2017-04-01)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
by: Ester Riepl, et al.
Published: (2018-01-01)

Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis
by: Tereza Gabelić, et al.
Published: (2021-11-01)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing–Remitting Multiple Sclerosis
by: Anna Bizoń, et al.
Published: (2023-08-01)

Vitamin D intoxication in a patient with relapsing-remitting multiple sclerosis – case report
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis
by: Sherein G. Elgendy, et al.
Published: (2021-10-01)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
by: Luis J. Pastor-Quirós, et al.
Published: (2021-10-01)

Exploring humanistic burden of fatigue in adults with multiple sclerosis: an analysis of US National Health and Wellness Survey data
by: Hoa H. Le, et al.
Published: (2024-02-01)